TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03220672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored assessment and educational
Description: Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
Study: NCT01243320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10ppm Oral Silver Particle
Description: Silver nanoparticles at 10ppm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 32ppm Oral Silver Particle
Description: Silver nanoparticles at 32ppm
Study: NCT04127448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming Training Group
Description: Training was given using X-box 360 Kinect. Dr. Kawashima's brain and body exercise game comprising of multiple cognitive games out of which 4 selected games were played by the participants. These games were Traffic control (participants have to guide the colored cars into their matching colored tunnels by using their arms), balloon buster (players pop numbered balloons in order from the lowest to the highest), pop till u drop, (match the color that appears on screen with the balloon of same color) and strike a pose (participant have to remember the poses shown and then copy them after few seconds). Games were played for 10 minutes initially then the duration was gradually increased to 30 minutes each session for 3 days/week and duration of 6 weeks. The session included 5-minute warm up, 20-minute interactive gaming, and 5-minute cool down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Group
Description: Session of 30-35 minutes, 3 days a week for 6 weeks was given using treadmill (model no TMX58 220). Time and intensity was gradually increased over the duration of 6 weeks. Starting from 10 minutes in 1st week, every 5 minutes was added to aerobics phase to each week until patient reached to 35 minutes in week 6 maintaining the intensity of 40-60% of heart rate reserve (%HRR).
Study: NCT01926184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)
Description: 5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: 12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management (CM)
Description: 12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
Study: NCT00788346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized alerts
Description: Computerized Clinical Decision Support to clinician at the time of prescribing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerts Plus Detailing
Description: Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
Study: NCT02568046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
Study: NCT00605787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetradecylthioacetic acid (TTA)
Description: 1000mg capsules once daily for 28 days
Study: NCT03709381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Cosyntropin (ACTH) stimulation test
Description: Cosyntropin 1 mcg IV given to subjects at t=0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Cosyntropin (ACTH) stimulation test
Description: Cosyntropin 250 mcg IV given to subjects at t=60
Study: NCT01675960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
Study: NCT03010644

Intervention type: OTHER
Intervention: n/a - observational study
Description: n/a - observational study
Study: NCT01313741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder arthroplasty with anchor peg glenoid
Description: Shoulder arthroplasty with anchor peg glenoid
Study: NCT02452788

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmaceutical care
Description: Pharmacist-provided education on medication adherence in hemodialysis patients.
Study: NCT03635658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: titanium mesh
Description: the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collagen membrane (Sausage technique)
Description: the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
Study: NCT01589653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
Study: NCT03890042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest group
Description: VISANNE 2MG Tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gestodene-Ethinyl Estradiol
Description: Gynera tablet once daily

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: ultrasound assessment of uterine volume

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: ultrasound assessment of uterine volume

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visual analogue scale
Description: visual analogue scale for assessment of pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visual analogue scale
Description: visual analogue scale for assessment of pain
Study: NCT01944852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icodextrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Study: NCT00918931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: 30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
Study: NCT00299611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
Study: NCT02922686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin
Description: One flucloxacillin capsule of 500mg strength taken four times daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flucloxacillin
Description: One flucloxacillin capsule of 500mg strength taken four times daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin
Description: One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for phenoxymethylpenicillin)
Description: Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
Study: NCT02809222

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaire
Description: Questionnaire to assess the quality of life of cancer patients

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaire
Description: Questionnaire to assess the quality of life of cancer patients
Study: NCT03811236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Two hours of mild cold exposure using a water-perfused vest
Study: NCT02408757

Intervention type: PROCEDURE
Intervention: Sonographic monitoring
Description: Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
Study: NCT02766556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: ISB with ropivacaine with dexmedetomidine or normal saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: ISB with ropivacaine with dexmedetomidine or normal saline

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ISB
Description: ISB with ropivacaine with dexmedetomidine or normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ISB with ropivacaine with dexmedetomidine or normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study: NCT03968133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral probiotic delivered in powdered form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo delivered in powdered form.
Study: NCT03680846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF10 Therapy
Description: Senza 10 kHz Spinal Cord Stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: CMM
Description: Conventional Medical Management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMM
Description: Conventional Medical Management
Study: NCT01051518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve System
Description: Transcatheter Aortic Valve
Study: NCT01224951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Description: 400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
Study: NCT04301310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235 (Treatment A)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin (Treatment B)
Description: Specified dose on specified days
Study: NCT01985672

Intervention type: PROCEDURE
Intervention: Frozen embryo transfer
Description: Embryo transfer of frozen/thawed embryos after IVF/ICSI

Intervention type: PROCEDURE
Intervention: Frozen embryo transfer
Description: Embryo transfer of frozen/thawed embryos after IVF/ICSI
Study: NCT00006089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT00923117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent (sunitinib)
Description: Oral dose 37.5 mg daily on a continuous 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent (sunitinib)
Description: Oral dose 37.5 mg daily on a continuous 4 week cycle
Study: NCT02815839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03060070

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
Study: NCT04497051

Intervention type: DIAGNOSTIC_TEST
Intervention: CT-DSA
Description: CTA before and after embolization
Study: NCT01389661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSV treatment
Description: Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
Study: NCT01343381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepalean Heparin
Description: 400 units per kilogram bolus prior to initiation of CPB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPC Heparin
Description: 400 unit per kilogram bolus prior to initiation of CPB
Study: NCT03753945

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI of the spine
Description: Perform a clinically indicated MRI of the spine in DBS patients
Study: NCT02161900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yogic and routine exercises
Description: All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogic and routine exercises
Description: All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
Study: NCT02194985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl 150 mg
Description: Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
Study: NCT04232618

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-biomarker point-of-care test
Description: Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-biomarker point-of-care test
Description: Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.
Study: NCT04038216

Intervention type: PROCEDURE
Intervention: Single-stage surgery
Description: the bone-anchored hearing implant will be inserted in one surgery

Intervention type: OTHER
Intervention: Two-stage surgery
Description: Two-stage surgery has already been performed, data will therefore be retrospectively collected
Study: NCT04072406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care packet
Description: Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
Study: NCT02867644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Patients coming for preoperative breast assessment will have standard care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care + conversational hypnosis
Description: Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
Study: NCT00682578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin + Piperaquine (Artekin)
Description: An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-sulphadoxin/pyrimethamine, chloroquine
Description: The standard treatment will be in accordance with that in Afghanistan
Study: NCT01676636

Intervention type: DRUG
Intervention: Traditional Tablet
Description: The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.

Intervention type: DRUG
Intervention: Chewable tablets
Description: Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.

Intervention type: DRUG
Intervention: Unflavoured Powder
Description: The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.

Intervention type: DRUG
Intervention: Flavoured Powder
Description: The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.